BioMedNewsBreaks

WednesdayJun 17, 2026 3:30 pm

BioMedNewsBreaks — Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Aligns with Growing Shift Toward Predictive, Precision Medicine

Cardio Diagnostics Holdings (NASDAQ: CDIO) is focused on personalized, data-driven cardiovascular care powered by artificial intelligence, epigenetics and genetic insights. “Through its proprietary platform and expanding testing capabilities, the company is pursuing a future in which prevention becomes more accessible, scalable and actionable before life-threatening cardiac events occur,” reads a recent article. “The company’s vision reflects a broader shift taking place across the healthcare industry toward predictive and precision medicine. Cardio Diagnostics envisions a healthcare system where every patient receives individualized care informed by their unique molecular insights and where heart disease is no longer the world’s leading killer. Achieving that goal…

Continue Reading

WednesdayJun 17, 2026 11:42 am

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Collaborates with Sysmex to Advance Nu.Q® NETs Assay Development

VolitionRx Limited (NYSE American: VNRX) announced a collaboration with Sysmex (TYO: 6869) to optimize Volition's Nu.Q® NETs H3.1 assay on the Sysmex diagnostic platform. The agreement supports Volition's strategy of licensing its proprietary Nu.Q® NETs technology to established global diagnostics companies that can leverage their disease expertise, regulatory capabilities and installed analyzer base to accelerate development and commercialization. Volition said the collaboration has progressed beyond assay transfer and into the optimization phase for diseases associated with NETosis, a process implicated in conditions including sepsis and other acute and chronic diseases. The company believes the Nu.Q® NETs assay could provide improved diagnostic information, support patient monitoring and address a commercial opportunity with an estimated total addressable market of $3.8…

Continue Reading

WednesdayJun 17, 2026 10:33 am

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Completes AI and Quantum Computing Pilot for PNKP Inhibitor Program 

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.  Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) announced the successful completion of a pilot project with Kuano Ltd. that supports advancement of the company's PNKP Inhibitor Technology (ONC010) through AI-enabled and quantum-based computational analysis. Kuano delivered molecular modeling and computational findings that strengthened Onco's understanding of how its PNKP inhibitor and related analogs may interact with the target, producing a refined structural hypothesis for PNKP inhibition and establishing a framework for structure-based optimization and future evaluation. The project also applied quantum-based computational methods to assess PNKP structural behavior and develop human PNKP structural models for follow-on…

Continue Reading

WednesdayJun 17, 2026 9:00 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances AI-Powered GMP Manufacturing Platform

Oncotelic Therapeutics (OTCQB: OTLC) announced the completion of key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, advancing commercialization of an AI-powered good manufacturing practices manufacturing services platform at SAPU Bio, the company's 45%-owned sterile injectable cGMP manufacturing joint venture. The Phase 2 deployment expands the capabilities of Oncotelic's proprietary PDAOAI(TM) platform across sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring and autonomous materials movement. The company said the integrated platform combines PDAOAI(TM) with TechForce's autonomous robotic systems to support intelligent pharmaceutical manufacturing and create potential opportunities in software licensing, automation deployment, manufacturing partnerships…

Continue Reading

TuesdayJun 16, 2026 1:57 pm

BioMedNewsBreaks — Humacyte Inc. (NASDAQ: HUMA) Prices $50 Million Public Offering 

Humacyte (NASDAQ: HUMA) announced the pricing of an underwritten public offering of 47.6 million shares of common stock at $1.05 per share, with expected gross proceeds of approximately $50 million before underwriting discounts, commissions and offering expenses. The company also granted underwriters a 30-day option to purchase up to an additional 7.1 million shares at the public offering price. The offering is expected to close on or about June 12, 2026, subject to customary closing conditions. Humacyte said it intends to use the net proceeds to support commercialization of Symvess(R), advance a planned Biologics License Application supplement filing for a hemodialysis indication, fund development of pipeline candidates and provide working capital…

Continue Reading

TuesdayJun 16, 2026 1:27 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Positioned at Intersection of Telemedicine, Pharmacy, Healthcare Services

Earth Science Tech (OTC: ETST) was featured in a recent article that discussed its significant transformation over the past several years, positioning as a diversified holding company focused on pharmaceutical compounding, telemedicine, healthcare services, and strict capital allocation. “The company recently completed a vertically integrated telehealth and pharmacy ecosystem through the launch of MyOnlineConsultation.com, with telemedicine capabilities supporting patient acquisition, while pharmacy operations drive high-margin recurring prescription-based revenue streams,” reads a recent article. “Above all, Earth Science Tech emphasizes balance-sheet strength and capital discipline through ongoing share repurchase initiatives designed to reduce dilution and support shareholder value.” To view the full…

Continue Reading

TuesdayJun 16, 2026 1:01 pm

BioMedNewsBreaks — Why VERAXA Biotech AG (NASDAQ: VRXA) Is ‘One to Watch’

VERAXA Biotech (NASDAQ: VRXA) is advancing a diversified oncology pipeline spanning monoclonal antibodies, antibody-drug conjugates, bispecific ADCs and proprietary BiTAC-based therapeutic formats across multiple cancer indications. “The company is focused on the discovery and development of a new generation of antibody-based therapeutics for the treatment of solid tumors. VERAXA’s vision is to deliver the next wave of smart cancer therapies with curative potential and improved safety profiles,” reads a recent article. “The company is building a pipeline that includes dual-targeting antibody-drug conjugates (‘ADCs’) and T-cell engagers (‘TCEs’) predominantly based on its patented BiTAC concept. This concept is designed to improve the…

Continue Reading

FridayJun 12, 2026 2:38 pm

BioMedNewsBreaks — Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Harnesses AI, Genetics and Epigenetics to Advance Cardiovascular Risk Detection

Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discusses the urgent need for more effective tools to identify risk earlier and guide personalized intervention strategies for cardiovascular disease. The piece reads, “Cardio Diagnostics is rising to the challenge by developing a suite of clinical, population health and biopharma solutions designed to leverage artificial intelligence (‘AI’), epigenetics and genetics to improve cardiovascular disease prevention, detection and management… The company’s platform is built around the integration of genetic and epigenetic biomarkers with AI-driven analytics to provide personalized cardiovascular insights from blood-based testing. Cardio Diagnostics currently offers two clinical solutions, Epi+Gen…

Continue Reading

ThursdayJun 11, 2026 3:58 pm

BioMedNewsBreaks — OptimizeRx Corp. (NASDAQ: OPRX) Secures $35 Million Senior Credit Facility 

OptimizeRx (NASDAQ: OPRX), a provider of healthcare technology solutions for life sciences companies, announced that it has entered into a $35 million senior secured credit facility with Fifth Third Bank. The facility consists of a $25 million term loan and a $10 million revolving credit facility that was undrawn at closing. Roth Capital Partners served as financial advisor on the transaction. To view the full announcement, visit https://ibn.fm/G0Fj3 About OptimizeRx OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant,…

Continue Reading

ThursdayJun 11, 2026 2:32 pm

BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Accelerates Development Strategy for Lead Candidate

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF), a Canadian life sciences company, was featured in a recent article that discussed the company’s efforts beginning a key phase of preclinical development for its lead drug candidate GEP-44, a multi-receptor peptide targeting obesity and type 2 diabetes. The publication reads, “The company is initiating a Good Laboratory Practice (‘GLP’) toxicology and pharmacology program aligned with U.S. Food and Drug Administration (‘FDA’) requirements, intended to support an Investigational New Drug (‘IND’) application and represents a necessary step before first-in-human clinical trials.…

Continue Reading